Clinical Trials Logo
  1. Home
  2. EBV
  3. NCT05677178

Response Prediction in EBV-HLH Using Metabonomics Analysis

Hemophagocytic Lymphohistiocytoses Clinical Trial

Official title:
Response Prediction in EBV-HLH Using Metabonomics Analysis

Clinical Trial Summary

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.

Clinical Trial Description

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Without early intervention, the median survival time is less than 2 months.Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets. ;

Study Design

Related Conditions & MeSH terms

  • EBV
  • Hemophagocytic Lymphohistiocytoses
  • Lymphohistiocytosis, Hemophagocytic
Clinical Trial Details
NCT number NCT05677178
Study type Observational [Patient Registry]
Source Beijing Friendship Hospital
Contact Zhao Wang, MD
Phone +861083138303
Email wangzhao@ccmu.edu.cn
Status Not yet recruiting
Phase
Start date January 1, 2023
Completion date March 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05491304 - Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis Phase 4
Completed NCT05531721 - HLH Patients - a Retrospective Study
Not yet recruiting NCT05600959 - Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
Completed NCT03546101 - Early Detection of Epstein-Barr Virus Related Disease.
Recruiting NCT05898477 - Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Recruiting NCT05882175 - Prospective Validation of the OHI Index
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Terminated NCT03985423 - A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Recruiting NCT03117010 - Prospective Cohort for Adult Hemophagocytosis
Not yet recruiting NCT06160791 - Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) Phase 2
Recruiting NCT05236764 - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion N/A
Recruiting NCT05277272 - INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
Completed NCT06047210 - Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
Not yet recruiting NCT05988177 - Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections N/A